Satellos Bioscience Stock Net Income
| MSCLF Stock | USD 0.90 0.04 4.65% |
As of the 27th of January, Satellos Bioscience has the Semi Deviation of 3.1, risk adjusted performance of 0.1496, and Coefficient Of Variation of 520.09. In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Satellos Bioscience, as well as the relationship between them. In other words, you can use this information to find out if the company will indeed mirror its model of past prices and volume data, or the prices will eventually revert. We were able to break down and interpolate nineteen technical drivers for Satellos Bioscience, which can be compared to its competition. Please validate Satellos Bioscience information ratio, value at risk, as well as the relationship between the Value At Risk and expected short fall to decide if Satellos Bioscience is priced more or less accurately, providing market reflects its prevalent price of 0.9 per share. Given that Satellos Bioscience is a hitting penny stock territory we recommend to closely look at its total risk alpha.
Satellos Bioscience's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Satellos Bioscience's valuation are provided below:Satellos Bioscience does not presently have any fundamental trend indicators for analysis. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. Satellos |
Satellos Bioscience 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Satellos Bioscience's otc stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Satellos Bioscience.
| 10/29/2025 |
| 01/27/2026 |
If you would invest 0.00 in Satellos Bioscience on October 29, 2025 and sell it all today you would earn a total of 0.00 from holding Satellos Bioscience or generate 0.0% return on investment in Satellos Bioscience over 90 days. Satellos Bioscience is related to or competes with Imugene, Biostem Technologies, Paradigm Biopharmaceutica, Starpharma Holdings, VitaSpring Biomedical, and Kintor Pharmaceutical. Satellos Bioscience Inc., a regenerative medicine company, develops therapeutics to treat degenerative muscle diseases More
Satellos Bioscience Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Satellos Bioscience's otc stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Satellos Bioscience upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 4.37 | |||
| Information Ratio | 0.1752 | |||
| Maximum Drawdown | 19.61 | |||
| Value At Risk | (5.88) | |||
| Potential Upside | 10.42 |
Satellos Bioscience Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Satellos Bioscience's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Satellos Bioscience's standard deviation. In reality, there are many statistical measures that can use Satellos Bioscience historical prices to predict the future Satellos Bioscience's volatility.| Risk Adjusted Performance | 0.1496 | |||
| Jensen Alpha | 0.9277 | |||
| Total Risk Alpha | 0.4443 | |||
| Sortino Ratio | 0.1905 | |||
| Treynor Ratio | (2.69) |
Satellos Bioscience January 27, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.1496 | |||
| Market Risk Adjusted Performance | (2.68) | |||
| Mean Deviation | 3.55 | |||
| Semi Deviation | 3.1 | |||
| Downside Deviation | 4.37 | |||
| Coefficient Of Variation | 520.09 | |||
| Standard Deviation | 4.75 | |||
| Variance | 22.59 | |||
| Information Ratio | 0.1752 | |||
| Jensen Alpha | 0.9277 | |||
| Total Risk Alpha | 0.4443 | |||
| Sortino Ratio | 0.1905 | |||
| Treynor Ratio | (2.69) | |||
| Maximum Drawdown | 19.61 | |||
| Value At Risk | (5.88) | |||
| Potential Upside | 10.42 | |||
| Downside Variance | 19.12 | |||
| Semi Variance | 9.63 | |||
| Expected Short fall | (5.25) | |||
| Skewness | 0.69 | |||
| Kurtosis | 0.6904 |
Satellos Bioscience Backtested Returns
Satellos Bioscience appears to be abnormally volatile, given 3 months investment horizon. Satellos Bioscience owns Efficiency Ratio (i.e., Sharpe Ratio) of 0.19, which indicates the firm had a 0.19 % return per unit of risk over the last 3 months. By inspecting Satellos Bioscience's technical indicators, you can evaluate if the expected return of 0.93% is justified by implied risk. Please review Satellos Bioscience's Risk Adjusted Performance of 0.1496, coefficient of variation of 520.09, and Semi Deviation of 3.1 to confirm if our risk estimates are consistent with your expectations. On a scale of 0 to 100, Satellos Bioscience holds a performance score of 15. The entity has a beta of -0.34, which indicates possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning Satellos Bioscience are expected to decrease at a much lower rate. During the bear market, Satellos Bioscience is likely to outperform the market. Please check Satellos Bioscience's value at risk and the relationship between the expected short fall and price action indicator , to make a quick decision on whether Satellos Bioscience's existing price patterns will revert.
Auto-correlation | -0.52 |
Good reverse predictability
Satellos Bioscience has good reverse predictability. Overlapping area represents the amount of predictability between Satellos Bioscience time series from 29th of October 2025 to 13th of December 2025 and 13th of December 2025 to 27th of January 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Satellos Bioscience price movement. The serial correlation of -0.52 indicates that about 52.0% of current Satellos Bioscience price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.52 | |
| Spearman Rank Test | -0.42 | |
| Residual Average | 0.0 | |
| Price Variance | 0.01 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, Satellos Bioscience reported net income of (15.51 Million). This is 104.54% lower than that of the Healthcare sector and 122.14% lower than that of the Biotechnology industry. The net income for all United States stocks is 102.72% higher than that of the company.
Satellos Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Satellos Bioscience's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the otc stocks which would be a good addition to a portfolio. Peer analysis of Satellos Bioscience could also be used in its relative valuation, which is a method of valuing Satellos Bioscience by comparing valuation metrics of similar companies.Satellos Bioscience is currently under evaluation in net income category among its peers.
Satellos Fundamentals
| Return On Equity | -0.86 | |||
| Return On Asset | -0.4 | |||
| Current Valuation | 7.17 M | |||
| Shares Outstanding | 41.8 M | |||
| Shares Owned By Insiders | 9.30 % | |||
| Shares Owned By Institutions | 14.41 % | |||
| Price To Book | 1.10 X | |||
| Price To Sales | 295.34 X | |||
| Gross Profit | (793.97 K) | |||
| EBITDA | (4.49 M) | |||
| Net Income | (15.51 M) | |||
| Cash And Equivalents | 1.93 M | |||
| Cash Per Share | 0.06 X | |||
| Current Ratio | 1.04 X | |||
| Book Value Per Share | 0.20 X | |||
| Cash Flow From Operations | (5.03 M) | |||
| Earnings Per Share | (0.47) X | |||
| Market Capitalization | 15.29 M | |||
| Total Asset | 12.59 M | |||
| Net Asset | 12.59 M |
About Satellos Bioscience Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Satellos Bioscience's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Satellos Bioscience using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Satellos Bioscience based on its fundamental data. In general, a quantitative approach, as applied to this otc stock, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in Satellos OTC Stock
Satellos Bioscience financial ratios help investors to determine whether Satellos OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Satellos with respect to the benefits of owning Satellos Bioscience security.